Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIMINATOR: Empagliflozin for MTX-linked Kidney Impairment in Rheumatoid Arthritis
jRCTs031250382Active, not recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in rheumatoid arthritis (RA) and chronic kidney disease (CKD), sponsored by University of Tsukuba Hospital. Primary endpoint: Incidence and types of adverse events. Started Dec 2025; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
rheumatoid arthritis (RA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs031250382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250382.